PCV

Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore

Retrieved on: 
Tuesday, April 16, 2024
Rabbit, AMD, Mouse, PCV, Tropism, Cell, AAV, Sf9, Gene, Society, Sf9 (cells), Molecular Therapy, HEK293, CGMP, Vaccine

HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.

Key Points: 
  • HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024.
  • In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package.
  • ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy.
  • Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations.

Dorman new releases for March include dozens of cost-saving repair solutions and aftermarket-exclusive innovations

Retrieved on: 
Tuesday, March 12, 2024
OE, F-150, CMCV, Ford, Dorman Products, Jeep Cherokee, Jeep, Infiniti, VIO, PCV, Safety, Coyote, Ram, Video game

More than half of the new releases are aftermarket firsts and dozens more are innovative repair solutions designed to save time or money.

Key Points: 
  • More than half of the new releases are aftermarket firsts and dozens more are innovative repair solutions designed to save time or money.
  • Underscoring Dorman’s status as the leading brand for technicians and dedicated DIYers, this month’s list adds to an unrivaled catalog of 122,000 SKUs.
  • That depth and diversity of coverage offers millions of new sales opportunities for automotive and heavy-duty parts distributors, retailers, and repair shops.
  • Two integrated door lock actuators, expanding Dorman’s lengthy list of products and applications for this category of critical safety assemblies.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024
SAN, Immunization, PCV, Serology, Life, Vaccine, Safety, Meningitis, Genetically modified bacteria, IPD, Tolerability, Infant, Disease, Streptococcus pneumoniae, Fungal infection

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
Licensure, Investment, Growth, Exercise, Tolerability, Immunization, Host, Trial of the century, Ageing, PCV20, PCV, P-value, Safety, BLA, Success, Phase 10, Genetically modified bacteria, Net, G&A, CMC, SAN, Research and development, ID, OPA, Conference, The Lancet, Biologics license application, Breakthrough therapy, Advisory Committee, PCV15, POC, FDA, End, Food, Breakthrough, Element, Fireside chats, Administration, IPD

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

Bonsai Data Solutions Introduces Overstory, the Marketing Industry's First-ever, First-party Data Platform

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Canopy (biology), Marketing, Algorithm, PCV, MMM, Advertising, Lead, Machine learning, Sales

CHICAGO, Feb. 21, 2024 /PRNewswire/ -- Bonsai Data Solutions, a data strategy and performance marketing innovation provider, today announced its flagship solution, Overstory, a marketing measurement and activation platform built on first-party data. The first-ever, first-party data platform for marketers, Overstory is the answer to the industry-wide challenges associated with tracking campaign results - including profit attribution - based on third-party cookies. Overstory empowers modern marketers to maximize the value of their own first-party data to collectively grow incremental business returns, and generate value from their advertising efforts.

Key Points: 
  • Business Leaders and Marketers Can Activate Their Own First-party Data, Gain a Unified View Across Sales and Marketing, and Say Goodbye to Third-party Data Reliance
    CHICAGO, Feb. 21, 2024 /PRNewswire/ -- Bonsai Data Solutions , a data strategy and performance marketing innovation provider, today announced its flagship solution, Overstory, a marketing measurement and activation platform built on first-party data.
  • The first-ever, first-party data platform for marketers, Overstory is the answer to the industry-wide challenges associated with tracking campaign results - including profit attribution - based on third-party cookies.
  • "For good reason, marketers have thrown their hands up over third-party data driven investments—they just don't work anymore," stated Matt Butler, CEO and co-founder of Bonsai.
  • Overstory platform solutions include:
    − Matched Market Testing—Leverage market-level marketing and business outcome data to identify matched markets, deploy and measure tests with speed, repeatability and confidence.

Standard Motor Products' Emission Control Program Expands

Retrieved on: 
Wednesday, February 7, 2024
Escape, EVAP, Altima, Wrangler, Trailblazer, PCV, OE, EGR, Accord, Ford Transit, Control, SMP, Catalog, Exploration, Compass, F-150, Subaru Outback, General Motors, Kia K5, Jeep, Subaru, Ford, Nissan, Standard, Dodge, Gasoline

NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) is dedicated to expanding its comprehensive Emission Control program. Standard's Emission Control program includes evaporative emission control (EVAP), exhaust gas recirculation (EGR), and positive crankcase ventilation emission control systems. With more than 3,500 part numbers, Standard® offers the most complete program in the industry, with everything needed for a complete repair.

Key Points: 
  • Standard's Emission Control program features more than 3,500 parts, including EVAP, EGR, and positive crankcase ventilation products
    SMP manufactures emission control components in its own North American facilities located in South Carolina, Kansas, and Mexico
    Standard® is committed to expanding its comprehensive emission control program, with new products continually released
    NEW YORK, Feb. 7, 2024 /PRNewswire/ -- Standard Motor Products, Inc. (SMP) is dedicated to expanding its comprehensive Emission Control program.
  • Standard's Emission Control program includes evaporative emission control (EVAP), exhaust gas recirculation (EGR), and positive crankcase ventilation emission control systems.
  • Standard® emission components are manufactured in three of SMP's North American facilities in Greenville, South Carolina, Independence, Kansas, and Reynosa, Mexico.
  • All new Standard® Emission Control applications are listed in the catalog found at StandardBrand.com and in electronic catalog providers.

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Retrieved on: 
Monday, January 29, 2024
Ageing, Biologics license application, SAN, Genetically modified bacteria, Public, IPD, Safety, Intend, PCV, Trial of the century, Vaccine

SAN CARLOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.

Key Points: 
  • -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in the U.S.
  • Adult Population --
    -- Company’s Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise, VAX-24 and VAX-31, Intended to Deliver the Broadest-Spectrum of Coverage Against IPD --
    SAN CARLOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 1/2 clinical study evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 1/2 study in the third quarter of 2024.
  • “Completing the enrollment of the VAX-31 study with more than one thousand adults 50 years and older is a significant step for our PCV franchise and we look forward to announcing topline safety, tolerability and immunogenicity data in the third quarter of this year,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Retrieved on: 
Thursday, January 4, 2024
Licensure, Food, PCV, End, Breakthrough therapy, FDA, CMC, Ageing, Phase 10, SAN, Pivotal, Biologics license application, Advisory Committee, PCV20, Breakthrough, Data monitoring committee, Immunization, Initiation, IPD, PCV15, Infant, Safety, Tolerability, Genetically modified bacteria, BLA, Vaccine

-- Enrollment in Ongoing VAX-24 Infant Phase 2 Study Continues to Progress; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 --

Key Points: 
  • Vaxcyte’s carrier-sparing PCV franchise candidates, including VAX-24, a 24-valent PCV proceeding to Phase 3, and VAX-31, the Company’s next-generation 31-valent PCV, are being studied for the prevention of invasive pneumococcal disease (IPD).
  • The VAX-24 Phase 2 infant study continues to enroll participants in the second and final stage of the study.
  • This is a randomized, observer-blind, dose-finding two-stage clinical study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy infants.
  • Topline safety, tolerability and immunogenicity data from the ongoing adult Phase 1/2 study in the third quarter of 2024.

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PCV, Risk, Death, Pneumonia, Streptococcus, Disease, Ageing, IVT, Vaccination, PATH, Meningitis, Bill, Safety, Sepsis, Vaccine

Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.

Key Points: 
  • Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.
  • This Phase 2 study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • The Inventprise PCV includes 25 serotypes—expanding the potential to prevent several deadly and emerging serotypes not yet addressed by existing PCVs.
  • A Phase 2 study in older adults is also planned to take place in the second half of 2024.

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Retrieved on: 
Monday, December 4, 2023
The Lancet, PCV, Death, Vaccine, Disease, Attenuated vaccine, SAN, PCV20, Public, IPD, Safety, Bacteria, Genetically modified bacteria

SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the publication of the results from the VAX-24 Phase 1/2 clinical proof-of-concept study in the journal The Lancet Infectious Diseases. This study evaluated the safety, tolerability and immunogenicity of Vaxcyte’s investigational 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) compared to the current standard-of-care, Prevnar 20® (PCV20), for the prevention of invasive pneumococcal disease (IPD) in healthy adults 18-64 years of age. The study results showed VAX-24 demonstrated a safety and tolerability profile that was comparable to PCV20 at all doses studied, and an immunogenicity profile that met or exceeded established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose. The Company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program.

Key Points: 
  • This study evaluated the safety, tolerability and immunogenicity of Vaxcyte’s investigational 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) compared to the current standard-of-care, Prevnar 20® (PCV20), for the prevention of invasive pneumococcal disease (IPD) in healthy adults 18-64 years of age.
  • The Company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program.
  • “Despite the availability of pneumococcal vaccines, the bacteria associated with IPD continues to be a major driver of deaths as a result of antimicrobial resistance.
  • “We look forward to initiating our Phase 3 pivotal, non-inferiority study, which is designed to further establish the clinical potential of VAX-24, and announcing topline data, which we expect in 2025.”